NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?

Key Takeaways Intellia stock plunged after the FDA placed a clinical hold on phase III studies of nex-z.The setback paused milestone guidance as Intellia works with regulators on next steps.NTLA eyes mid-2026 data for lonvo-z, which could become a key catalyst for the stock.Shares of Intellia Therapeutics (NTLA) have witnessed a sharp decline in the past month, primarily due to a regulatory setback faced with one of its lead in vivo candidates, nex-z (formerly known as NTLA-2001), as well as the mixed third ...